Dr. Naval Daver presented results of ENHANCE-3 study at EHA2024

Talha Badar shared on X:         .

“Dr. Naval Daver: Presented results of ENHANCE-3 study; magrolimab and venetoclax and AZA vs AZA and VEN in newly diagnosed AML (Acute myelogenous leukemia).

1) The trial did not show improvement in CR or OS with triplet.

2) Magrolimab combination led to more fatal AEs (grade 5)

Although a negative study which is unfortunate, but we should acknowledge the efforts and hard work put in by investigators in this trial!”

Source: Talha Badar/X

Dr. Talha Badar, MD, is a specialist in Hematology Oncology based in Mayo Clinic, Jacksonville, Florida. His primary areas of expertise include Leukemia, particularly Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Acute Lymphoblastic Leukemia (ALL), and Bone Marrow Transplantation. Over his career, he has actively contributed to clinical research and clinical trials.